Home / Market News / $ABT
benzinga Corporate Catalyst Impact 75/100 ● neutral

Abbott Laboratories Sees Q4 Adj EPS $1.62-$1.67 vs $1.64 Est

Oct 21, 2026, 11:31 AM UTC · Primary ticker $ABT

Abbott Laboratories has provided its Q4 adjusted EPS guidance, projecting a range of $1.62 to $1.67. This range straddles the current analyst consensus estimate of $1.64, indicating a mixed outlook that could lead to moderate stock price volatility.

Abbott Laboratories (ABT) has released its Q4 adjusted EPS guidance, forecasting a range of $1.62 to $1.67. This guidance is significant because it directly compares to the analyst consensus estimate of $1.64. The fact that the range includes and slightly exceeds the estimate on the high end, but also falls below it on the low end, creates uncertainty. This could lead to short-term volatility in ABT's stock as investors digest whether the company is likely to beat, meet, or miss expectations. For traders, the key opportunity lies in anticipating market reaction to the midpoint of the guidance versus the consensus, and how this might influence sentiment ahead of the official earnings report.

$ABT neutral Q4 EPS guidance straddles analyst estimates
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.